News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
